New data argue that multimers of α-synuclein may protect against pathological aggregation.
A study of nearly 2 million people reports that obesity lowers dementia risk, while being underweight raises it.
At the AD/PD conference, researchers reported a protective gene variant that delays Alzheimer’s onset by 10 years, and parsed pathways to find out why particular neurons take the hit in specific diseases.
Peptides made from D-amino acids bind to Aβ oligomers and trigger their removal from the brain. Some appear poised to enter Phase 1.
The highs and lows of cerebrospinal fluid Aβ and PET amyloid imaging don't necessarily agree.
In the presynaptic terminals of the hippocampus, pathological aggregates of tau weakened calcium influx and plasticity. A little later, the synapses disappeared.
By dampening translation, these tiny RNAs keep protein levels from fluctuating wildly.
Qualification could follow, but only if trial sponsors fork over fresh data.
A screen in round worms identifies a novel mechanism for degradation of toxic proteins.
Two new open-access journals will cover specialized areas of Alzheimer’s research.
Epigenetic changes in the C9ORF72 promoter do not prevent disease, but they do decelerate brain atrophy and memory loss.
The newest contender in the race for a drug to rein in the β-secretase enzyme debuted with data that reflected a methodical approach to understand a drug’s performance in cerebrospinal fluid before looking for efficacy.
Treatments targeting the main pathological protein of Parkinson’s disease are moving toward the clinic, with two immunotherapies passing Phase 1 safety benchmarks.
Biogen Antibody Buoyed by Phase 1 Data and Hungry Investors Antibody Against α-Synuclein Looks Safe In Phase 1 At AD/PD Meeting, New BACE Inhibitor Struts Its Stuff D-peptides as Drugs? Protein Therapy Approaching Phase 1 Trials New Genetics Frontiers: ...
Microbleeds in the brain portend either stroke or cardiovascular events, depending on where they occur.